Mill Capital Management LLC Boosts Stake in Zoetis Inc. $ZTS

Mill Capital Management LLC raised its stake in shares of Zoetis Inc. (NYSE:ZTS) by 6.8% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 173,822 shares of the company’s stock after buying an additional 11,122 shares during the quarter. Zoetis comprises about 1.6% of Mill Capital Management LLC’s investment portfolio, making the stock its 21st biggest position. Mill Capital Management LLC’s holdings in Zoetis were worth $20,547,000 as of its most recent filing with the SEC.

Other hedge funds also recently bought and sold shares of the company. Global Wealth Strategies & Associates acquired a new stake in shares of Zoetis during the fourth quarter valued at $25,000. Prosperity Bancshares Inc acquired a new position in Zoetis in the 4th quarter valued at about $25,000. KERR FINANCIAL PLANNING Corp acquired a new position in Zoetis in the 3rd quarter valued at about $31,000. Lodestone Wealth Management LLC purchased a new position in Zoetis in the 4th quarter valued at about $30,000. Finally, Elyxium Wealth LLC purchased a new position in Zoetis in the 4th quarter valued at about $32,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent research reports. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. HSBC reduced their price objective on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. UBS Group lowered their target price on shares of Zoetis from $130.00 to $99.00 and set a “neutral” rating for the company in a research note on Friday, May 8th. Barclays lowered their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 1st. Finally, Citigroup reduced their price target on Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. Eight equities research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Zoetis has a consensus rating of “Hold” and a consensus target price of $123.46.

Zoetis Stock Down 1.7%

ZTS opened at $74.08 on Wednesday. Zoetis Inc. has a 12 month low of $71.47 and a 12 month high of $160.48. The business has a 50-day moving average of $78.40 and a two-hundred day moving average of $106.94. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91. The stock has a market capitalization of $31.06 billion, a price-to-earnings ratio of 12.29, a price-to-earnings-growth ratio of 1.18 and a beta of 0.75.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The company had revenue of $2.26 billion for the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the company earned $1.48 earnings per share. The company’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. On average, research analysts expect that Zoetis Inc. will post 6.88 earnings per share for the current year.

Zoetis Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 annualized dividend and a yield of 2.9%. Zoetis’s dividend payout ratio is 35.16%.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis announced a deal to acquire VitalRADS, a provider of veterinary imaging services, which could support growth in its animal-health business by expanding diagnostic capabilities. Zoetis to acquire VitalRADS, a provider of veterinary imaging services
• Neutral Sentiment: Several firms, including Rosen, Glancy Prongay Wolke & Rotter, the Gross Law Firm, Levi & Korsinsky, and others, issued reminders about the Zoetis securities class action and the upcoming deadline, increasing the amount of negative press but not adding new case details. Pomerantz law firm investor alert
• Negative Sentiment: The class action alleges Zoetis and certain executives made misleading statements about companion-animal product performance while safety concerns and competitive losses were building, which is weighing on investor sentiment. ZTS shareholder alert
• Negative Sentiment: The stock also appears to be reflecting a weaker trading tone after recent earnings disappointment, with Zoetis having previously missed analyst estimates on EPS and revenue, adding to concerns about near-term fundamentals. Zoetis stock dips while market gains: key facts

Insiders Place Their Bets

In related news, Director Michael B. Mccallister purchased 3,000 shares of the business’s stock in a transaction on Monday, May 11th. The shares were bought at an average price of $77.76 per share, with a total value of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares in the company, valued at approximately $1,906,986.24. This trade represents a 13.94% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Frank A. Damelio purchased 6,650 shares of the firm’s stock in a transaction on Wednesday, May 13th. The stock was bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the acquisition, the director owned 21,458 shares in the company, valued at $1,617,718.62. The trade was a 44.91% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased a total of 11,650 shares of company stock valued at $886,384 over the last quarter. Company insiders own 0.22% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.